- Voluntis in collaboration with Bristol-Myers Squibb announced a collaboration in digital therapeutics
- Initial development to be focused around Oncology
Paris based Voluntis, a leader in digital therapeutics, is all set to collaborate with Bristol-Myers Squibb, an American pharmaceutical giant, to develop a digital therapeutic solution to aid and assist cancer patients.
Voluntis’s digital therapeutics platform for oncology, has been identified as an ideal platform to collaborate and analyze patient symptom data with the remote monitoring offered by the healthcare industry. This method of symptom assessment would help in saving time as well as other resources for patients. A mobile or a computer application will also be developed to support cancer treatment and track the symptoms in real time.
As claimed on Voluntis’s website the main goal for the development of such an application is “Patients report symptom data in the smartphone app to receive immediate actionable recommendations that are personalized to their profile and current condition” and “Care teams can follow the progress of their entire patient population from their desks thanks to their web app, no download needed”
Voluntis’s Theraxium Oncology also supports the development of new designs and algorithms with interoperable workflows. This helps the patient procure real time recommendations and also helps them to self-manage symptoms and medication related to their therapy. Both the collaborators are also looking in to the possibility which could enable patients to effectively communicate with healthcare professionals, track and report symptoms as well as help them in getting the required medical advice and a guidance plan.